Anemia, Hemolytic, Autoimmune: all 99 studies

Page 1 of 1. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07816341Phase 1
• HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.RecruitingNCT07748533Phase 1
• META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07689604Early Phase 1
• Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)RecruitingNCT07629596Early Phase 1
• Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)Not yet recruitingNCT07603557Phase 2
• IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07585071Phase 1
• Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675
• CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related CytopeniaNot yet recruitingNCT07574073Phase 1
• A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic AnemiaNot yet recruitingNCT07518277Not applicable
• Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07453836Phase 1
• Orelabrutinib in the Treatment of Relapsed/Refractory AIHARecruitingNCT07453368Phase 2
• UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesRecruitingNCT07441525Early Phase 1
• A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07287930Phase 1
• A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaRecruitingNCT07205315Early Phase 1
• A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic AnemiaNot yet recruitingNCT07190261Phase 2
• A Study of CM336 in Patients With Relapsed or Refractory Autoimmune CytopeniaRecruitingNCT07175493Phase 1/2
• A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07149818
• Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of TherapyNot yet recruitingNCT07091370Phase 1
• A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaRecruitingNCT07086976Phase 3
• OM336 in Autoimmune CytopeniasRecruitingNCT07083960Phase 1
• National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic AnemiaRecruitingNCT07019038
• UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune DiseasesNot yet recruitingNCT06978738Phase 1
• Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic AnemiaRecruitingNCT06921980
• UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic AnemiaNot yet recruitingNCT06920446Early Phase 1
• Safety Study of CC312 in Autoimmune Disease PatientsRecruitingNCT06888960Early Phase 1
• A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)Not yet recruitingNCT06847607Not applicable
• A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT06770504Phase 1
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.RecruitingNCT06733610Phase 1
• CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of TherapyRecruitingNCT06212154Phase 1
• The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
• Anti-CD38 Antibody Treating Evans SyndromeRecruitingNCT06014775Phase 2
• OBS'CEREVANCE: French Cohort of Pediatric Autoimmune CytopeniaRecruitingNCT05937828
• Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune NeutropeniaRecruitingNCT05931718
• Zanubrutinib in the Treatment of Relapsed/Refractory wAIHARecruitingNCT05922839Phase 2
• Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
• Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter StudyRecruitingNCT05089227Phase 2
• Second-line Treatment of Primary Autoimmune Hemolytic AnemiaRecruitingNCT05057468Phase 3
• The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After TratmentNot yet recruitingNCT04814394
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationNCT04138927Phase 3
• Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune CytopeniaRecruitingNCT04005638
• French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic AnemiaRecruitingNCT02877706
• Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in JapanCompletedNCT05132127Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)CompletedNCT05096403Phase 3Results posted
• Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological DisordersTerminatedNCT05086744Phase 2Results posted
• Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)TerminatedNCT04661033Phase 2Results posted
• Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT04657094Phase 2Results posted
• To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).TerminatedNCT04253236Phase 2Results posted
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedNCT03764618Phase 3Results posted
• A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaCompletedNCT03538041Phase 2Results posted
• A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood TransfusionCompletedNCT03347422Phase 3Results posted
• A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)CompletedNCT03347396Phase 3Results posted
• Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)CompletedNCT03226678Phase 2Results posted
• A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)TerminatedNCT03075878Phase 1/2Results posted
• Sirolimus for Autoimmune Disease of Blood CellsCompletedNCT00392951Phase 1/2Results posted
• Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT07361094Phase 1
• A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaCompletedNCT07075484Phase 1
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus ErythematosusCompletedNCT06653556Early Phase 1
• CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.Active, not recruitingNCT06231368Phase 1
• Cold Agglutinin Disease Real World Evidence RegistryActive, not recruitingNCT05791708
• An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedNCT05757570Phase 1/2
• Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.Status unknownNCT05711264
• PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of TherapyTerminatedNCT05676697Phase 1
• A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisStatus unknownNCT05263817Early Phase 1
• Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusStatus unknownNCT05057481Phase 3
• Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic AnemiaWithdrawnNCT04956276Phase 2
• Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088TerminatedNCT04802057Phase 1
• The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
• A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin DiseaseCompletedNCT04269551Phase 1
• ALXN1830 in Patients With Warm Autoimmune Hemolytic AnemiaWithdrawnNCT04256148Phase 2
• Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic AnemiaCompletedNCT04083014Phase 2
• National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.CompletedNCT04070612
• Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.CompletedNCT04057703
• A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITPWithdrawnNCT04039477Phase 2
• Data Registry of Auto Immune Hemolytic AnemiaStatus unknownNCT04024202
• Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune CytopeniaWithdrawnNCT03965624Phase 2
• Tacrolimus Treatment for Refractory Autoimmune CytopeniaStatus unknownNCT03918265Phase 4
• Ibrutinib in Steroid Refractory Autoimmune Hemolytic AnemiaStatus unknownNCT03827603Phase 2
• Severe Immune Cytopenia Registry Www.Sic-reg.OrgCompletedNCT03576742
• Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic AnemiaCompletedNCT03269292
• Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)CompletedNCT02828670
• Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseCompletedNCT02689986Phase 2
• A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)CompletedNCT02612558Phase 2
• Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersCompletedNCT02502903Phase 1
• Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional TreatmentTerminatedNCT02389231Phase 1/2
• Immunopathology of Autoimmune Hemolytic AnemiaCompletedNCT02158195
• Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin DiseaseCompletedNCT01696474Phase 2
• Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.Status unknownNCT01579110Phase 2
• A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaCompletedNCT01345708Phase 2
• Therapy of Chronic Cold Agglutinin Disease With EculizumabCompletedNCT01303952Phase 2
• Rituximab in Auto-Immune Hemolytic AnemiaCompletedNCT01181154Phase 3
• Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaCompletedNCT01134432Phase 3
• The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune DisordersCompletedNCT00960713
• Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasCompletedNCT00749112Phase 2/3
• Therapy for Chronic Cold Agglutinin DiseaseCompletedNCT00373594Phase 2
• Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)CompletedNCT00309881Phase 2
• Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic DiseaseCompletedNCT00010387Phase 2
• Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesStatus unknownNCT00006055Not applicable
• Treatment of Autoimmune Thrombocytopenia (AITP)CompletedNCT00001630Phase 1

← Anemia, Hemolytic, Autoimmune overview